Latest news and press releases about Design Therapeutics, Inc. (DSGN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications.
Price
| Price | $12.51 |
| Market Cap | $781M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.79 |
| EV / EBITDA | -12.65 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -34.03% |
| Return on Invested Capital | -38.92% |
| Return on Assets | -32.91% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · AURA · DMAC · ENGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of DSGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks